Related Experiment Video
Updated: Jun 17, 2025
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
1.8K
Management of Chronic Heart Failure with Reduced Ejection Fraction.
Brandon Williamson1, Carl Tong2
1From the Texas A&M University Health Science Center, Bryan, TX (BW); Texas A&M University Health Science Center, Bryan, TX (CT). Bwilliamson@tamu.edu.
Journal of the American Board of Family Medicine : JABFM
|August 14, 2024
Summary
This review covers guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF). It details established treatments and newer options like sacubitril-valsartan and SGLT2 inhibitors for chronic HFrEF management.
Area of Science:
- Cardiology
- Pharmacology
- Family Medicine
Background:
- Heart failure with reduced ejection fraction (HFrEF) is a prevalent condition encountered in family practice.
- Effective pharmacologic management is crucial for improving patient outcomes and quality of life.
Purpose of the Study:
- To provide a comprehensive overview of the pharmacologic management of chronic HFrEF.
- To highlight the latest American Heart Association guidelines for guideline-directed medical therapy (GDMT).
Main Methods:
- Review of current literature and clinical guidelines.
- Detailed discussion of established and emerging pharmacologic agents for HFrEF.
- Focus on classification, GDMT, and comorbidity management.
Main Results:
- Established therapies including beta-blockers, ACE inhibitors, ARBs, and MRAs remain foundational.
- Newer agents such as sacubitril-valsartan and SGLT2 inhibitors represent significant advancements in HFrEF treatment.
- Comprehensive management also involves addressing comorbidities and considering advanced therapies.
Conclusions:
- Adherence to GDMT, incorporating novel therapies, is essential for optimal HFrEF care.
- Family physicians play a key role in managing chronic HFrEF with evidence-based pharmacologic strategies.
- Continuous updates in treatment recommendations necessitate ongoing professional development in HFrEF management.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K